A new light-driven cancer therapy uses LEDs and tin nanoflakes to kill tumors safely and affordably. Developed by teams in Texas and Portugal, it eliminates up to 92% of skin cancer cells without ...

Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%.

"After a prolonged and courageous battle with cancer, we are heartbroken to announce that Michael D'Angelo Archer, known to his fans around the world as D'Angelo, has been called home, departing this ...

Scientists are hoping to treat diseases including cancer and Alzheimer's by influencing how cells make life-or-death decisions.

Scientists at University of California San Diego have developed a new approach to destroying cancer stem cells—hard-to-find cells that help cancers spread, come back after treatment and resist therapy ...

Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage and side effects. Now, researchers at Cornell's Weill Institute for Cell ...

A double-pronged attack on advanced prostate cancer could help treat as many as two in five patients with late-stage disease, scientists have found. Using drugs that are already being used to treat ...

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or ...

Blocking structural changes may restore the effectiveness of the cancer drug venetoclax, according to Rutgers Health researchers and others ...

Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling advanced prostate cancer. Experts at The Institute of Cancer Research, London, ...

Renowned actor Pankaj Dheer has passed away after a prolonged battle with cancer, drawing attention to why the disease often returns even after successful treatment. Experts say cancer relapse happens ...

Trodelvy reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The median progression-free survival ...